Abstract:To assess unloaded knee extensor temporal strength changes, healthy subjects without asthma performed 40 continuous days of unilateral limb suspension, whereby their left leg refrained from normal weight-bearing and ambulatory activity. During the 40-day period, subjects performed resistance exercise (REX) with their unloaded leg on an inertial resistance ergometer and, as part of a double-blind design, consumed the maximal oral therapeutic dosage of albuterol (i.e., 16 mg.d) or a placebo (i.e., lactose) with … Show more
“…Le Panse et al did employ DXA scanning during 3‐4 weeks of oral salbutamol ingestion (12 mg/d), but employed a cross‐over design, which makes small changes in lean mass difficult to detect, as subjects who started with the salbutamol treatment most likely did not revert to baseline lean mass in the 4‐week washout period . In addition, studies that examined effects of salbutamol on body composition used self‐reported records as a measure of drug compliance, and lack of observed effects of salbutamol may therefore be attributed to low drug adherence. Indeed, studies show low drug compliance when relying on self‐reported records, being as low as 50% when the study drug is to be taken several times daily, as was the case for these studies .…”
Section: Discussionmentioning
confidence: 99%
“…In addition, studies that examined effects of salbutamol on body composition used self‐reported records as a measure of drug compliance, and lack of observed effects of salbutamol may therefore be attributed to low drug adherence. Indeed, studies show low drug compliance when relying on self‐reported records, being as low as 50% when the study drug is to be taken several times daily, as was the case for these studies . In addition, side effects associated with beta 2 ‐agonists may be unpleasant, and participants may deviate from the dosing regimen they were asked to follow .…”
Section: Discussionmentioning
confidence: 99%
“…It should be noted that in the present study, the hypertrophic effect of terbutaline was blunted when combined with non‐weight‐bearing exercise (ie, cycling), and whether this observation holds true for weight‐bearing exercise such as running is not known. When combined with resistance training, on the other hand, oral ingestion of salbutamol has been shown to enhance adaptations in muscle strength after limb unloading . In a recent study, Dickinson et al observed no additional effect of 6 weeks of daily inhalation of 400 μg salbutamol 4 times daily compared to placebo in training induced changes in muscle strength and skinfold thickness incurred from concurrent endurance and resistance training in young men.…”
Due to a high prevalence of asthma and exercise-induced bronchoconstriction in elite athletes, there is a high use of beta 2 -adrenoceptor agonists (beta 2 -agonists) in the athletic population. While anabolic in rodents, no study has been able to detect hypertrophy in humans after chronic beta 2 -agonist inhalation. We investigated whether inhaled beta 2 -agonist, terbutaline, alters body composition and metabolic rate with and without concurrent exercise training in healthy young men. Sixty-seven participants completed a 4-week intervention of daily terbutaline (8 × 0.5 mg) or placebo treatment without concurrent training (habitual; n = 23), with resistance (n = 23) or endurance (n = 21) training 3 times weekly. Before and after the interventions, participant's body composition was determined by dual-energy X-ray absorptiometry and resting metabolic rate and substrate oxidation by indirect calorimetry. Terbutaline increased lean body mass by 1.03 kg (95% CI 0.29-1.76; P < .05) and 1.04 kg (95% CI 0.16-1.93; P < .05) compared to placebo in the habitual and resistance training group, respectively, but had no effect compared to placebo in the endurance training group [−0.56 kg (95% CI −1.74-0.62; P > .05)]. Fat mass, bone mineral content, and resting metabolic rate did not change differently between treatments with the intervention. Daily inhalation of terbutaline in near-therapeutic doses induces skeletal muscle growth. This observation should be a concern for antidoping authorities. K E Y W O R D S adrenergic, athletes, beta-agonist, doping, physical activity How to cite this article: Jessen S, Onslev J, Lemminger A, Backer V, Bangsbo J, Hostrup M. Hypertrophic effect of inhaled beta 2 -agonist with and without concurrent exercise training: A randomized controlled trial. Scand J Med Sci Sports. 2018;28:2114-2122.
“…Le Panse et al did employ DXA scanning during 3‐4 weeks of oral salbutamol ingestion (12 mg/d), but employed a cross‐over design, which makes small changes in lean mass difficult to detect, as subjects who started with the salbutamol treatment most likely did not revert to baseline lean mass in the 4‐week washout period . In addition, studies that examined effects of salbutamol on body composition used self‐reported records as a measure of drug compliance, and lack of observed effects of salbutamol may therefore be attributed to low drug adherence. Indeed, studies show low drug compliance when relying on self‐reported records, being as low as 50% when the study drug is to be taken several times daily, as was the case for these studies .…”
Section: Discussionmentioning
confidence: 99%
“…In addition, studies that examined effects of salbutamol on body composition used self‐reported records as a measure of drug compliance, and lack of observed effects of salbutamol may therefore be attributed to low drug adherence. Indeed, studies show low drug compliance when relying on self‐reported records, being as low as 50% when the study drug is to be taken several times daily, as was the case for these studies . In addition, side effects associated with beta 2 ‐agonists may be unpleasant, and participants may deviate from the dosing regimen they were asked to follow .…”
Section: Discussionmentioning
confidence: 99%
“…It should be noted that in the present study, the hypertrophic effect of terbutaline was blunted when combined with non‐weight‐bearing exercise (ie, cycling), and whether this observation holds true for weight‐bearing exercise such as running is not known. When combined with resistance training, on the other hand, oral ingestion of salbutamol has been shown to enhance adaptations in muscle strength after limb unloading . In a recent study, Dickinson et al observed no additional effect of 6 weeks of daily inhalation of 400 μg salbutamol 4 times daily compared to placebo in training induced changes in muscle strength and skinfold thickness incurred from concurrent endurance and resistance training in young men.…”
Due to a high prevalence of asthma and exercise-induced bronchoconstriction in elite athletes, there is a high use of beta 2 -adrenoceptor agonists (beta 2 -agonists) in the athletic population. While anabolic in rodents, no study has been able to detect hypertrophy in humans after chronic beta 2 -agonist inhalation. We investigated whether inhaled beta 2 -agonist, terbutaline, alters body composition and metabolic rate with and without concurrent exercise training in healthy young men. Sixty-seven participants completed a 4-week intervention of daily terbutaline (8 × 0.5 mg) or placebo treatment without concurrent training (habitual; n = 23), with resistance (n = 23) or endurance (n = 21) training 3 times weekly. Before and after the interventions, participant's body composition was determined by dual-energy X-ray absorptiometry and resting metabolic rate and substrate oxidation by indirect calorimetry. Terbutaline increased lean body mass by 1.03 kg (95% CI 0.29-1.76; P < .05) and 1.04 kg (95% CI 0.16-1.93; P < .05) compared to placebo in the habitual and resistance training group, respectively, but had no effect compared to placebo in the endurance training group [−0.56 kg (95% CI −1.74-0.62; P > .05)]. Fat mass, bone mineral content, and resting metabolic rate did not change differently between treatments with the intervention. Daily inhalation of terbutaline in near-therapeutic doses induces skeletal muscle growth. This observation should be a concern for antidoping authorities. K E Y W O R D S adrenergic, athletes, beta-agonist, doping, physical activity How to cite this article: Jessen S, Onslev J, Lemminger A, Backer V, Bangsbo J, Hostrup M. Hypertrophic effect of inhaled beta 2 -agonist with and without concurrent exercise training: A randomized controlled trial. Scand J Med Sci Sports. 2018;28:2114-2122.
“…Thus, beta 2 ‐adrenergic‐induced changes in O 2max and muscle oxidative enzymes may be confounded by particular types of training. Furthermore, in spite of the studies on the beta 2 ‐adrenergic effects on muscle strength in response to resistance training, no studies have, to our best knowledge, investigated whether concurrent resistance training affects adaptations in absolute and relative O 2max as well as in muscle oxidative enzymes in response to chronic beta 2 ‐adrenergic agonist treatment. As such, while absolute O 2max may be unaltered by chronic beta 2 ‐adrenergic agonist treatment, their hypertrophic effect may compromise O 2max relative to body mass or lean mass.…”
While beta2‐adrenoceptor stimulation has been shown to increase lean mass and to alter metabolic properties of skeletal muscle, adaptations in muscle oxidative enzymes and maximal oxygen uptake (trueV˙O2max) in response to beta2‐adrenergic agonist treatment are inadequately explored in humans, particularly in association with resistance training. Herein, we investigated beta2‐adrenergic‐induced changes in trueV˙O2max, leg and arm composition, and muscle content of oxidative enzymes in response to treatment with the selective beta2‐adrenergic agonist terbutaline with and without concurrent resistance training in young men. Forty‐six subjects were randomized to 4 weeks of lifestyle maintenance (n = 23) or resistance training (n = 23). Within the lifestyle maintenance and resistance training group, subjects received daily terbutaline (8 × 0.5 mg) (n = 13) or placebo (n = 10) treatment. No apparent treatment by training interactions was observed during the study period. Terbutaline increased leg and arm lean mass with the intervention, whereas no treatment differences were observed in absolute trueV˙O2max and incremental peak power output (iPPO). Treatment main effects were observed for trueV˙O2‐reserve (P < .05), trueV˙O2max relative to body mass (P < .05), trueV˙O2max relative to leg lean mass (P < .01), and iPPO relative to leg lean mass, in which terbutaline had a negative effect compared with placebo. Furthermore, content of electron transport chain complex I‐V decreased by 11% (P < .05) for terbutaline compared with placebo. Accordingly, chronic treatment with the selective beta2‐adrenergic agonist terbutaline may negatively affect trueV˙O2max and iPPO in relative terms, but not in absolute.
“…Thus, the present study also showed a significant main effect of gender in aerobic performance, with lower estimated VO 2max values in active female than male athletes after the MFST. In contrast, during supra‐maximal exercise after salbutamol intake (3‐4 weeks, 12 mg daily), some studies showed no potentiating effects of gender (Caruso et al, 2008; Le Panse et al, 2005). In addition, no significant differences were observed between males and females in both groups for RPE value in the current study.…”
This study aimed to investigate the effects of beta2‐agonist terbutaline sulfate (TER) at a supra‐therapeutic dose (8 mg) on aerobic exercise performance. Twelve (6 females and 6 males) amateur athletes familiarized with all experimental procedures had their anthropometric data obtained on day 1. On days 2 and 3 either 8 mg of TER or a placebo (PLA) was administered orally (double‐blind manner) to participants who had rested for 3 h prior to aerobic exercise performance 20 m multistage fitness test (MSFT)]. This test was used to predict maximal oxygen uptake (VO2max) and velocity at which VO2max occurs (vVO2max). The Borg rating of perceived exertion (RPE), cardiovascular variables [heart rate (HR) and blood pressure (BP)] and blood glucose concentration [BGC] were obtained 15 min pre‐ and immediately post‐MSFT. Significant mean group differences were reported between PLA and TER groups (p < 0.05), respectively, in the RPE (15.6 ± 1.2 vs. 17.3 ± 1.5 a.u.), maximum heart rate (HRmax: 191.2 ± 7.1 vs. 197.2 ± 8.6 bpm) and BGC (118.4 ± 18.3 vs. 141.2 ± 15.8 mg/dL) post‐MSFT. The main effect of gender (male vs. female) in TER and PLA groups (p< 0.05) was observed, with higher estimated VO2max, vVO2max, HRmax and a lower mean HR pre‐test in male than female athletes. For these reasons, the inclusion of TER in the Prohibited List should be re‐discussed because of the lack of ergogenic effects.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.